Legato Capital Management LLC Sells 14,663 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Legato Capital Management LLC decreased its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 32.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,167 shares of the company’s stock after selling 14,663 shares during the period. Legato Capital Management LLC’s holdings in PROCEPT BioRobotics were worth $2,510,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Values First Advisors Inc. acquired a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at about $27,000. Raleigh Capital Management Inc. acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Wilmington Savings Fund Society FSB bought a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $64,000. Canton Hathaway LLC acquired a new stake in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $66,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of PROCEPT BioRobotics by 178.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock valued at $89,000 after acquiring an additional 713 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on PRCT. Morgan Stanley began coverage on shares of PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an “overweight” rating and a $105.00 target price on the stock. Truist Financial reissued a “buy” rating and set a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price for the company. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and a consensus target price of $97.86.

PROCEPT BioRobotics Trading Down 5.4 %

PRCT opened at $66.00 on Wednesday. PROCEPT BioRobotics Co. has a fifty-two week low of $45.20 and a fifty-two week high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company’s 50-day moving average is $80.71 and its 200 day moving average is $79.65.

Insiders Place Their Bets

In related news, EVP Alaleh Nouri sold 28,092 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the transaction, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Reza Zadno sold 26,420 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total transaction of $2,584,668.60. Following the completion of the sale, the chief executive officer now directly owns 179,185 shares of the company’s stock, valued at $17,529,668.55. The trade was a 12.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,355 shares of company stock valued at $10,327,788. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).